Opthea (ASX:OPT) announced the publication of data from a phase 2b trial of its sozinibercept drug candidate for wet age-related macular degeneration in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina, according to a Monday Australian bourse filing.
The paper reports pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-naïve patients.
The randomized, controlled trial saw sozinibercept combination therapy leading to superior visual gains compared to therapy with only ranibizumab at 24 weeks.
Analysis of the data showed that in patients with occult and minimally classic lesions, representing 73% of the Phase 2b total patient population, sozinibercept combination therapy demonstrated a "statistically significant" gain in best corrected visual acuity compared to ranibizumab alone.
Opthea's shares rose almost 3% in recent trading on Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。